A 2026 controlled study of 96 people found severe long-COVID fatigue across 3 validated fatigue scales, but the tested peripheral inflammation, cellular-stress, neuroprotection, and autoimmunity markers did not significantly differ by group or explain fatigue severity.1 The finding argues against a simple blood-marker story, not against the reality of long-COVID fatigue. Research Highlights Fatigue was …
A 2025 Journal of the American Chemical Society study identified 4 unusual Morganella morganii phospholipids that activated TLR2/TLR1 immune receptors and induced inflammatory cytokines, especially IL-6.1 The finding does not prove that one gut bacterium causes depression, but it gives the microbiome-depression field something it often lacks: a named molecule and a receptor pathway. Research …
The depression-inflammation literature has firmly established that elevated inflammatory markers track with mood symptoms, but a 2026 study of 14,419 postpartum women from Xie et al. found the opposite pattern for postpartum anxiety: women with higher second-trimester platelet-neutrophil products and related immune-inflammation indices had substantially lower postpartum anxiety risk.1 Research Highlights Higher second-trimester PPN was …
Whole-body hyperthermia looks less like generic relaxation and more like a timed biological stressor: in a small depression substudy, a single session was followed by early Hamilton Depression Rating Scale improvement, heat-shock gene activation, and immune-process enrichment that included interleukin 6 production. Research Highlights Depression scores improved early: in the 18-person RNA sequencing substudy, whole-body …
A 2026 NHANES mortality analysis found that adults with PHQ-9 depressive symptoms had lower long-term all-cause mortality when their CALLY index was higher: in the fully adjusted model, each 1-unit higher log-CALLY value carried a hazard ratio of 0.59, with a 95% confidence interval from 0.51 to 0.68.1 The useful interpretation is prognostic, not therapeutic: …
A 2026 exploratory analysis of the ABCD cancer dyspnea trial found that higher baseline cytokines predicted less placebo symptom improvement than lower baseline cytokines across 33 of 40 cytokine-symptom combinations at day 7 and 29 of 40 at day 14.1 The signal is not ready for clinical prediction, but it sharpens a trial-design problem: patients …
The broad cytokine story failed its most direct community test: in 972 adults, depression, alcohol use, and alcohol use disorder (AUD) were not associated with C-reactive protein (CRP) or a pre-registered pro-inflammatory cytokine index. The only multiple-testing-corrected cytokine hits ran opposite the hypothesis — AUD was linked to lower IL-1β, IL-4, IL-10, and IL-12 — …